Key facts
- It has raised $124.0M; the latest was Early Stage VC ($59.0M) in Sep 2025.
- Notable investors include Qiming Venture Partners, OrbiMed, 5Y Capital, Lapam Capital, Beijing Xicheng Jinrui Equity Investment Fund Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Epigenic
- ·The full record, as it builds
Funding rounds
No funding rounds for Epigenic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epigenic
Developer and provider of gene-silencing technology designed for multiple diseases. The company is committed to regulating a variety of diseases through epigenome editing, creating gene editing therapies, which can be used to cure ophthalmology, neurodegeneration, metabolism, and rare diseases, providing effective treatments to patients with chronic and severe diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- epigenictx.com/
- Ownership
- Privately Held (backing)
Epigenic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epigenic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epigenic in its N-PORT filings yet. We sweep new filings monthly.